Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand

Haemophilia

Volumn 10, Issue 1, 2004, Pages 18-26

  Stonebraker, Jeffrey S ^a   Amand, R E ^a   Bauman, M V ^a   Nagle, A J ^b   Larson, P J ^a  

^a BAYER CORPORATION   (United States)

^b NOVOZYMES A S   (Denmark)

Author keywords

Decision analysis; Epidemiology; Haemophilia A; Probability; Treatment; Unconstrained factor VIII demand

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG USE; FEMALE; FORECASTING; HEALTH CARE FINANCING; HEALTH CARE NEED; HEALTH CARE POLICY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL LITERATURE; MODEL; PRIORITY JOURNAL; PROBABILITY; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS;

EID: 1042286883     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00841.x     Document Type: Article

References (46)

1. Bohn RL, Colowick AB, Avorn J. Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatment. Haemophilia 1999; 5: 374-7.
2. Brown SA, Aledort LM, Lee CA et al. Optimal treatment regimens for patients with bleeding disorders. Haemophilia 2001; 7: 313-20.
3. Ljung RC. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost 1999; 82: 525-30.
4. World Federation of Hemophilia. Report on the WFH Global Survey 2001. Montreal, Canada: WFH, 2001.
5. Lozier JN, Kessler CM. Clinical aspects and therapy of hemophilia. In: Hoffman R, ed. Hematology: Basic Principles and Practice. 3rd edn. Philadelphia, PA: Churchill Livingstone, 2000.
6. Abt R, Borja M, Menke MM, Pezier JP. The dangerous quest for certainty in market forecasting. Long Range Plann 1979; 12: 52-62.
7. Keefer DL, Bodily SE. Three-point approximation for continuous random variables. Manage Sci 1983; 29: 595-609.
8. Keefer DL. Facilities evaluation under uncertainty: pricing a refinery. Interfaces 1995; 25: 57-66.
9. Spetzler CS, Staël von Holstein C-AS. Probability encoding in decision analysis. Manage Sci 1975; 22: 340-52.
10. Balthasar HU, Boschi RAA, Menke MM. Calling the shots in R&D. Harv Bus Rev 1978; 56: 151-60.
11. Boschi RAA, Balthasar HU, Menke MM. Quantifying and forecasting exploratory research success. Res Manage 1979; 22: 14-21.
12. Merkhofer MW. Quantifying judgmental uncertainty: methodology, experiences, and insights. IEEE Trans Syst Man Cybern 1987; SMC-17: 741-52.
13. Shephard GG, Kirkwood CW. Managing the judgmental probability elicitation process: a case study of analyst/manager interaction. IEEE Trans Eng Manag 1994; 41: 414-25.
14. Walker I, Pai M, Akabutu J et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-51.
15. Soucie JM, Evatt B, Jackson D and the Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
16. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
17. Centers for Disease Control and Prevention. Hemophilia Surveillance System Report, Vol. 1 No. 2. Atlanta, GA: CDC, 1999.
18. Lusher JM. Treatment of congenital coagulopathies. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press, 1999.
19. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program (UDC), Vol. 4 No. 1. Atlanta, GA: CDC, 2002.
20. United Nations. The Sex and Age Distribution of the World Populations. The 1996 Revision. New York, NY: UN, 1997.
21. Centers for Disease Control and Prevention. CDC Growth Charts for the United States. Atlanta, GA: CDC, 2000.
22. Ljung RC. Aspects of haemophilia prophylaxis in Sweden. Haemophilia 2002; 8 (Suppl. 2): 34-37.
23. Van Den Berg HM, Fischer K, Van Der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 8 (Suppl. 2): 43-46.
24. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
25. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
26. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
27. Ljung RC. Can haemophilic arthropathy be prevented? Br J Haematol 1998; 101: 215-9.
28. Tusell J, Perez-Bianco R. Prophylaxis in developed and in emerging countries. Haemophilia 2002; 8: 183-8.
29. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
30. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
31. Lusher JM. Recombinant clotting factor concentrates. Baillieres Clin Haematol 1996; 9: 291-303.
32. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 203-6.
33. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
34. Kulkarni R, Aledort LM, Berntorp E et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67: 240-6.
35. Manno CS. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia 1999; 5 (Suppl. 3): 33-41.
36. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
37. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 568-73.
38. Engelfriet CP, Reesink HW, Mannucci PM et al. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Vox Sang 2000; 78: 256-61.
39. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
40. DiMichele DM, Kroner BL, the ISTH Factor VIII/IX Subcommittee. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-1997): current practice implications. Blood 1997; 90 (Suppl. 1): 156A.
41. Poland WB. Simple probabilistic evaluation of portfolio strategies. Interfaces 1999; 29: 75-83.
42. Market Research Bureau Inc. The Plasma Fractions Market in Asia and Pacific - 2000. Vol. A, B and C. Orange, CT: MRB, 2001a.
43. Market Research Bureau Inc. The Plasma Fractions Market in the United States - 2000. Orange, CT: MRB, 2001b.
44. Market Research Bureau Inc. The Plasma Fractions Market in the Middle East - 2000. Orange, CT: MRB, 2001c.
45. Market Research Bureau Inc. The Plasma Fractions Market in Europe - 1999. Vol. A, B and C. Orange, CT: MRB, 2000.
46. Market Research Bureau Inc. The Plasma Fractions Market in Central and South America - 1998. Vol. A and B. Orange, CT: MRB, 1999.